Garwood Medical Device, LLC, a Buffalo NY-based company which specializes in developing technology to treat antibiotic-resistant bacterial biofilm infections associated with metallic orthopaedic implants, raised $4M in Series C funding.
The round was led by the WNY Impact Investment Fund and the Murray family, along with global investors in the orthopaedics/health care space.
The company intends to use the funds to expand operations and its business reach.
Led by Wayne Bacon, president & CEO, Garwood Medical Devices is developing technology to eliminate antibiotic-resistant bacterial biofilm infections associated with metallic orthopaedic implants. Its BioPrax™ device is currently under investigation to study the elimination of biofilm infections on prosthetic knee implants during early intervention procedures and used alongside the current standard of care. It is currently in pre-clinical trials.